Southland Equity Partners’s Novartis NVS Stock Holding History
Bought
Maintained
Sold
Other funds holding NVS
Southland Equity Partners's NVS Position: Q2 2026 in Review
Southland Equity Partners increased its Novartis (NVS) stake by 3.3% in Q2 2026, buying an estimated $18.3K and bringing the position to 3,807 shares worth $597K. The position accounts for 0.1% of the portfolio, ranked #146.
Southland Equity Partners first reported a position in NVS in Q4 2021 and has held it in 17 quarters since. 1,617 funds tracked by Wall St. Rank hold NVS as of Q2 2026.
- Southland Equity Partners held 3,807 shares of Novartis worth $597K as of Q2 2026.
- Southland Equity Partners bought 122 Novartis shares in Q2 2026, an estimated $18.3K.
- Novartis made up 0.1% of Southland Equity Partners's portfolio in Q2 2026, its #146 holding.
- Southland Equity Partners first reported a position in Novartis in Q4 2021 and has held it in 17 quarters since.
- 1,617 funds tracked by Wall St. Rank held Novartis as of Q2 2026.
Based on Southland Equity Partners's 13F filing for Q2 2026, filed 13 Jul 2026.